Skip to content
naulon
Not checkedNot checked for notices yet.

The role of carfilzomib in relapsed/refractory multiple myeloma

Andrew J. Yee

Therapeutic Advances in Hematology · 2021

doi:10.1177/20406207211019612 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.

Abstract licence: CC BY-NC

References70

    40 more references, whose wording the paper’s licence keeps private.

    All 70 references

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.